Pursuing our commitment to health

2021/2022 Integrated Annual Report

FOCUS

The Servier R&D Institute in Paris-Saclay: innovation and value creation

In 2023, nearly 1,200 Servier employees will start working at our new Research and Development (R&D) Institute in Paris-Saclay. As a hub for scientific excellence, the Institute will strive to create value for all its stakeholders, including patients, our teams, the Paris-Saclay campus as a whole, as well as the wider French research community.

40 %

Paris-Saclay represents 40% of French research jobs in the public and private sector in the Greater Paris region

8

Paris-Saclay is one of eight largest innovation hubs in the world*

* Ranking established by the Technology Review published by the Massachussets Institute of Technology (MIT)

Testimonial

“This unique hub of research and development will stimulate our ambition to provide cutting-edge therapeutic innovations to patients, reflecting our determination to raise the profile of French research internationally.

We are therefore pursuing a future-focused project that will drive our long-term research—the cornerstone of the Group’s success—and fulfill our vocation to champion therapeutic progress that serves patient needs.”

Therapeutic innovation and the potential of artificial intelligence

For several years, medical research has been profoundly transformed by the emergence of artificial intelligence (AI). This technology makes it possible to speed up certain stages of the R&D process, which means we are able to develop medicines faster and open the way to more tailored treatments, in particular online, as reflected in our ambition to become a Digital Performer.

2021/2022 Financial results

Our 2021/2022 financial results are in line with our 2025 trajectory and put us on the right track to fulfill our ambitions for 2030. The increased volume of sales throughout the world reflects our drive to make ever-more medicines available to the patients who need them. Our independence, underpinned by being governed by a non-profit Foundation, enables us to finance growth as we are free to reinvest all our profits to develop our business.

Our medicines and therapeutic areas

Day in, day out, we capitalize on the engagement of the people employed throughout the Group in order to make our brand-name and generic medicines available to patients in over 150 countries.

Cancer

A focused and innovative player developing targeted therapies to treat cancer

Cardio metabolism

A strong commitment for over 60 years

Neuroscience

A commitment to satisfy a major medical need

Immuno-inflammation

Bring forward new treatment options

Discover our non-financial
indicators 2021/2022

Non-financial indicators 2021/2022